TLL-018 for moderate-to-severe atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an investigational medicine called TLL-018 (taken by mouth) for people with moderate-to-severe atopic dermatitis (also known as eczema). The goal is to see if it reduces symptoms like itching and skin patches, and to check for safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had atopic dermatitis (eczema) for at least 1 year.
- Your eczema is moderate to severe, affecting at least 16% of your body (EASI score 16 or higher) and with significant itching.
- You have tried topical treatments (like creams or ointments) for eczema that did not work well enough, or you need stronger (systemic) treatment.
- You are willing to use a mild moisturizer (emollient) twice daily throughout the study.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 90 days after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.